A stability-indicating HPLC method for the separation of clarithromycin and related substances in bulk samples
dc.contributor.author | Abuga, Kennedy O. | |
dc.contributor.author | Chepkwony, Hezekiah K. | |
dc.contributor.author | Roets, Eugene | |
dc.contributor.author | Hoogmartens, Jos | |
dc.date.accessioned | 2013-02-18T13:33:13Z | |
dc.date.issued | 2001-11 | |
dc.identifier.citation | J. Sep. Science, 24: 849–855. | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10125 | |
dc.description.abstract | Clarithromycin is a 6-O-methylated semi-synthetic derivative of erythromycin A, which is more resistant towards acid decomposition. Commercial clarithromycin samples contain several potential impurities arising from the manufacturing process and degradation. A simple, selective, and sensitive isocratic liquid chromatographic method has been developed for the impurity profiling of clarithromycin bulk samples. The method employs a XTerra RP18, 5 μm, 250×4.6 mm column thermostated at 56°C. The mobile phase consists of acetonitrile – 0.2 M potassium phosphate buffer pH 6.80 – water (40 : 3.5 : 56.5). Several peaks are of unknown identity. The method is stability indicating. | en |
dc.language.iso | en | en |
dc.subject | Liquid chromatography | en |
dc.subject | Clarithromycin | en |
dc.subject | XTerra RP18 | en |
dc.title | A stability-indicating HPLC method for the separation of clarithromycin and related substances in bulk samples | en |
dc.type | Article | en |
local.embargo.terms | 6 months | en |
local.embargo.lift | 2013-08-17T13:33:13Z |
Files in this item
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]